Gracell Biotechnologies Inc. Receives Average Rating of Moderate Buy from Analysts - MarketBeat
| GRCLDelisted Stock | USD 4.02 0.26 6.07% |
About 61% of Gracell Biotechnologies' investor base is looking to short. The analysis of current outlook of investing in Gracell Biotechnologies suggests that many traders are alarmed regarding Gracell Biotechnologies' prospects. Gracell Biotechnologies' investing sentiment shows overall attitude of investors towards Gracell Biotechnologies.
Gracell |
Gracell Biotechnologies Inc. Receives Average Rating of Moderate Buy from Analysts MarketBeat
Read at news.google.com
 |
Gracell Biotechnologies Fundamental Analysis
We analyze Gracell Biotechnologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gracell Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gracell Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Gracell Biotechnologies is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Gracell Biotechnologies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Gracell Biotechnologies stock to make a market-neutral strategy. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics with similar companies.
Peers
Gracell Biotechnologies Related Equities
| GLUE | Monte Rosa | 13.72 | ||||
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| CTMX | CytomX Therapeutics | 3.92 | ||||
| BOLT | Bolt Biotherapeutics | 1.59 | ||||
| DAWN | Day One | 1.53 | ||||
| BPMC | Blueprint Medicines | 1.35 | ||||
| ASMB | Assembly Biosciences | 1.25 | ||||
| SPRO | Spero Therapeutics | 0.88 | ||||
| DSGN | Design Therapeutics | 0.50 | ||||
| ABOS | Acumen Pharmaceuticals | 0.44 | ||||
| INZY | Inozyme Pharma | 0.37 | ||||
| TERN | Terns Pharmaceuticals | 1.58 | ||||
| ERAS | Erasca | 2.05 | ||||
| NXTC | NextCure | 2.50 | ||||
| CHRS | Coherus BioSciences | 3.17 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.48 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |